BioWorld. Link to homepage.
BioWorld
BioWorld MedTech
BioWorld Asia
BioWorld Science
Data Snapshots
BioWorld
BioWorld MedTech
Infographics: Dynamic digital data analysis
Special reports
Infographics: Dynamic digital data analysis
Women's health
China's GLP-1 landscape
PFA re-energizes afib market
China CAR T
Alzheimer's disease
Israel
Rise of obesity
Radiopharmaceuticals
Biosimilars
Aging
IVDs on the rise
Coronavirus
Artificial intelligence
Premium reports
BioWorld Financings Reports
Disease Incidence & Prevalence Summaries
BioWorld. Link to homepage.
sign in
Sign Out
My Account
Subscribe
BioWorld - Sunday, December 22, 2024
See today's BioWorld MedTech
See today's BioWorld Asia
See today's BioWorld
Home
» Aprinoia gets NMPA nod for PET imaging tracer 18F-APN-1607 phase III trials in China
X
Upgrade your daily dose of biopharma and medtech news
Subscribe to BioWorld™ news services
See subscription options
To read the full story,
subscribe
or
sign in
.
Aprinoia gets NMPA nod for PET imaging tracer 18F-APN-1607 phase III trials in China
Nov. 3, 2020
By
Gina Lee
No Comments
HONG KONG – Aprinoia Therapeutics Inc. is poised to start phase III clinical trials for its positron emission tomography (PET) imaging tracer 18F-APN-1607 in China, after receiving the green light from the National Medical Products Administration.
BioWorld
BioWorld MedTech
BioWorld Asia
Clinical
Neurology/psychiatric
Diagnostics
Imaging
Asia-Pacific
China
